PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26606286-1 2016 PURPOSE: The aim of this study was to characterize the healing in rabbit calvarial bone defects after delivery of limited-dose (1.5 mug) Escherichia coli-derived recombinant human bone morphogenetic protein-2 (ErhBMP-2), and evaluate biphasic calcium phosphate (BCP) as a carrier. hydroxyapatite-beta tricalcium phosphate 262-265 bone morphogenetic protein 2 Homo sapiens 180-208 25675839-1 2016 OBJECTIVES: This study compared the bone regenerative effects of a recombinant human bone morphogenetic protein 2 (rhBMP-2)-loaded collagen-based biphasic calcium phosphate composite (BCPC) and rhBMP-2-loaded biphasic calcium phosphate (BCP). hydroxyapatite-beta tricalcium phosphate 184-187 bone morphogenetic protein 2 Homo sapiens 85-113 24889783-5 2015 Furthermore, Smad1, 4, 5, and Dlx5, the main molecules in the BMP/Smads signaling pathway, were upregulated by HA and BCP. hydroxyapatite-beta tricalcium phosphate 118-121 bone morphogenetic protein 2 Homo sapiens 62-65 27815469-8 2016 From these results, it can be concluded that BMP2 activated BCP for the enhancement of bone regeneration. hydroxyapatite-beta tricalcium phosphate 60-63 bone morphogenetic protein 2 Homo sapiens 45-49 23651333-1 2014 OBJECTIVES: The purpose was to evaluate the effect of Escherichia coli-derived recombinant human bone morphogenetic protein-2 (ErhBMP-2)-/epigallocatechin-3-gallate (EGCG)-coated biphasic calcium phosphate (BCP) and titanium barrier membrane on dehiscence defects in dogs. hydroxyapatite-beta tricalcium phosphate 207-210 bone morphogenetic protein 2 Homo sapiens 97-125 24935525-0 2014 In vitro and in vivo studies of BMP-2-loaded PCL-gelatin-BCP electrospun scaffolds. hydroxyapatite-beta tricalcium phosphate 57-60 bone morphogenetic protein 2 Homo sapiens 32-37 24931105-1 2014 PURPOSE: The objectives of this study were to confirm the osteogenic potential of the Schneiderian membrane and to elucidate the early healing pattern of low-dose recombinant human bone morphogenetic protein-2 (rhBMP-2)-coated biphasic calcium phosphate (BCP). hydroxyapatite-beta tricalcium phosphate 255-258 bone morphogenetic protein 2 Homo sapiens 181-209 11077412-2 2001 BCP ceramics impregnated with different doses of recombinant human bone morphogenetic protein 2 (rhBMP-2) (1, 5, and 10 microg) were used for experimental purposes and ceramics without rhBMP-2 were used for control. hydroxyapatite-beta tricalcium phosphate 0-3 bone morphogenetic protein 2 Homo sapiens 67-95 23830037-1 2013 OBJECTIVE: The aim of the study was to analyze the value of Escherichia coli-derived recombinant human bone morphogenetic protein-2 (ErhBMP-2) coated biphasic calcium phosphate (BCP) for the obliteration of middle ear bone defect after mastoid surgery. hydroxyapatite-beta tricalcium phosphate 178-181 bone morphogenetic protein 2 Homo sapiens 103-131 23559460-7 2013 Similarly, HA-S and BCP-S particles had a larger amount of the adsorbed BMP-2 per gram solid than HA-C did. hydroxyapatite-beta tricalcium phosphate 20-25 bone morphogenetic protein 2 Homo sapiens 72-77 23075297-10 2013 In conclusion, 15 min BMP-2 preincubation of hASCs seeded on BCP/beta-TCP scaffolds had a long-lasting stimulating effect on osteogenic differentiation in vitro. hydroxyapatite-beta tricalcium phosphate 61-64 bone morphogenetic protein 2 Homo sapiens 22-27 22733619-1 2012 Block-type biphasic calcium phosphate (BCP) carriers are more effective at delivering recombinant human bone morphogenetic protein-2 (rhBMP-2) in various clinical situations than are particle-type carriers, due to their potential for highly successful three-dimensional bone regeneration. hydroxyapatite-beta tricalcium phosphate 39-42 bone morphogenetic protein 2 Homo sapiens 104-132 29240243-8 2018 Additionally, differentiation studies of human mesenchymal stem cells (hMSCs) on BCP/ZrO2 scaffolds in static and dynamic culture conditions showed increased expression of bone morphogenic protein-2 (BMP-2) when cultured on BCP/ZrO2 scaffolds under dynamic conditions compared to on BCP control scaffolds. hydroxyapatite-beta tricalcium phosphate 81-84 bone morphogenetic protein 2 Homo sapiens 172-198 29240243-8 2018 Additionally, differentiation studies of human mesenchymal stem cells (hMSCs) on BCP/ZrO2 scaffolds in static and dynamic culture conditions showed increased expression of bone morphogenic protein-2 (BMP-2) when cultured on BCP/ZrO2 scaffolds under dynamic conditions compared to on BCP control scaffolds. hydroxyapatite-beta tricalcium phosphate 81-84 bone morphogenetic protein 2 Homo sapiens 200-205 29240243-8 2018 Additionally, differentiation studies of human mesenchymal stem cells (hMSCs) on BCP/ZrO2 scaffolds in static and dynamic culture conditions showed increased expression of bone morphogenic protein-2 (BMP-2) when cultured on BCP/ZrO2 scaffolds under dynamic conditions compared to on BCP control scaffolds. hydroxyapatite-beta tricalcium phosphate 224-227 bone morphogenetic protein 2 Homo sapiens 172-198 29240243-8 2018 Additionally, differentiation studies of human mesenchymal stem cells (hMSCs) on BCP/ZrO2 scaffolds in static and dynamic culture conditions showed increased expression of bone morphogenic protein-2 (BMP-2) when cultured on BCP/ZrO2 scaffolds under dynamic conditions compared to on BCP control scaffolds. hydroxyapatite-beta tricalcium phosphate 224-227 bone morphogenetic protein 2 Homo sapiens 200-205 33819813-1 2021 This study aimed to fabricate a multi-layered biphasic calcium phosphate (BCP) platform for programmed bone morphogenetic protein-2 (BMP-2) release, which means to block the initial burst release and promote releasing during the differentiation phase of osteogenic cells. hydroxyapatite-beta tricalcium phosphate 74-77 bone morphogenetic protein 2 Homo sapiens 103-131 33819813-1 2021 This study aimed to fabricate a multi-layered biphasic calcium phosphate (BCP) platform for programmed bone morphogenetic protein-2 (BMP-2) release, which means to block the initial burst release and promote releasing during the differentiation phase of osteogenic cells. hydroxyapatite-beta tricalcium phosphate 74-77 bone morphogenetic protein 2 Homo sapiens 133-138 31098332-1 2019 Purpose: The aim of this study was to evaluate the enhancement of osteogenic potential of biphasic calcium phosphate (BCP) bone substitute coated with Escherichia coli-derived recombinant human bone morphogenetic protein-2 (ErhBMP-2) and epigallocatechin-3-gallate (EGCG). hydroxyapatite-beta tricalcium phosphate 118-121 bone morphogenetic protein 2 Homo sapiens 194-222